8 news items
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
CGTX
7 May 24
-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease
CGTX
22 Apr 24
. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
CGTX
2 Apr 24
biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
CGTX
26 Mar 24
and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
CGTX
15 Mar 24
:Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative
9r742qd8kfy7pvfruah0h 6r5ad2npv3tq535zkdsxdpr
BSFC
CGTX
EKSO
15 Mar 24
company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders
3qo9v56
CGTX
11 Mar 24
in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous
zufk96t6uk8ofx7ja0qqvfs2n8o7wg76a
CGTX
6 Mar 24
. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age
- Prev
- 1
- Next